{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":26,"n_cols":5,"rows_kept":26,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[13,2,13,3],[14,2,14,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910465114403321"]
[null,null,"Autore",null,"Dark Graham"]
[null,null,"Titolo",null,"Oncology at a glance [[electronic resource] /] / Graham G. Dark"]
[null,null,"Pubbl/distr/stampa",null,"Chichester, West Sussex, U.K., : Wiley-Blackwell, 2013"]
[null,null,"ISBN",null,"1-118-27214-5"]
[{"$nulls":4},"1-118-36970-X"]
[null,null,"Descrizione fisica",null,"1 online resource (138 p.)"]
[null,null,"Collana",null,"At a glance"]
[null,null,"Disciplina",null,"616.99/4"]
[null,null,"Soggetti",null,"Oncology - Methodology"]
[{"$nulls":4},"Tumors - Diagnosis"]
[{"$nulls":4},"Tumors - Treatment"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Cover; Title page; Copyright page; Contents; Contributors; Preface; Abbreviations; 1: The global burden of cancer; The global burden of cancer; Developed and developing countries; Tobacco; Lifestyle; Infections; Challenges; 2: The nomenclature of oncology; Tumour nomenclature; Tumour grade; Cytology; Cytogenetic analysis; Tumour stage; Performance status; 3: Environmental determinants of cancer; Environmental factors; Radiation; Chemicals; Smoking; Infections; Hormones; Nutrition and lifestyle; 4: The hallmarks of cancer I; The 10 hallmarks of cancer; 1. Genome instability and mutation"]
[{"$nulls":4},"2. Resisting cell death5: The hallmarks of cancer II; 3. Sustaining proliferative signalling; The cell cycle; Cell cycle regulation; Stimulation of the cell cycle; 4. Evading growth suppressors; 5. Enabling replicative immortality; 6: The hallmarks of cancer III; 6. Inducing angiogenesis; 7. Activating invasion and metastasis; 7: The hallmarks of cancer IV; 8. Reprogramming energy metabolism; 9. Tumour-promoting inflammation; 10. Evading immune destruction; 8: Cancer genetics and inherited cancer; Principles of cancer genetics; How genes cause cancer; Oncogenes; Tumour suppressor genes"]
[{"$nulls":4},"Multistep carcinogenesisInherited cancer syndromes; Autosomal dominant cancer syndromes; Autosomal recessive cancer syndromes; 9: Communicating with cancer patients; Communicating with cancer patients; The doctor-patient relationship; Breaking bad news; Steps to breaking bad news; Dealing with the emotional patient; Communicating "]
[{"$nulls":4},"with younger patients; 10: Presenting problems in a patient with cancer; Presenting features of cancer; General features on examination; Local effects; Change of function; Obstruction of a conduit; Metastatic effects; 11: Paraneoplastic syndromes"]
[{"$nulls":4},"Ectopic hormone productionNeurological manifestations; Cutaneous manifestations; Haematological manifestations; Gastrointestinal manifestations; Renal manifestations; Other paraneoplastic syndromes; 12: Metabolic emergencies in cancer patients; Hypercalcaemia; Syndrome of inappropriate antidiuresis; Hypomagnesaemia; Tumour lysis syndrome; 13: Oncological emergencies; Neutropenic sepsis; Superior vena cava obstruction; Spinal cord compression; 14: Investigation and management of metastatic disease; Brain metastases; Lung metastases; Liver metastases; Bone metastases; Malignant pleural effusion"]
[{"$nulls":4},"Malignant ascitesOther sites; 15: Tumour markers; Serum proteins; Clinical usefulness; Human chorionic gonadotrophin; Alpha-fetoprotein; Placental alkaline phosphatase; CA19-9; Inhibin; Carcinoembryonic antigen (CEA); CA15-3; CA125; Squamous cell carcinoma-associated antigen (SCC); Prostate-specific antigen (PSA); Hormones; 16: Screening for cancer; Successful screening; Lead time bias; Length time bias; Breast cancer screening; Colorectal cancer screening; Gastric cancer screening; Prostate cancer screening; Cervical cancer screening; Ovarian cancer screening; Lung cancer screening"]
[{"$nulls":4},"The future"]
[null,null,null,"Sommario/riassunto","This brand new title in the market-leading at a Glance series brings together fundamental information on cancer biology and treatment to provide a holistic understanding of oncology. It explores both relevant scientific content and key human issues, including communication and palliative care.Oncology at a Glance: Provides an accessible overview of the scientific foundation of cancer medicine Covers the common cancers as well as key information on presentation and approaches to investigation and management Includes young adult oncology, t"]